Pear Therapeutics — SPAC Merger (June 2021)
54 slides from Pear Therapeutics's SPAC merger presentation, Jun 22, 2021
Slide 1: Prescription Digital Therapeutics Software for the Treatment of Serious Disease
Exhibit 99.5 Prescription Digital Therapeutics Software for the Treatment of Serious Disease Investor Presentation June 2021 1 Copyright 2021, Pear Therapeutics, Inc. All rights reserved. Exhibit 99.5 Prescription Digital Therapeutics Software for the Treatment of Serious Disease Investor Presentati
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation ( Presentation ) contains proprietary and confidential information of Thimble Point Acquisition Corporation (“TPAC ) and Pear Therapeutics, Inc. (the “Company”), and the entire content should be considered “Confidential Information” with
Slide 3: Disclaimer: Use of Projections
Disclaimer USE OF PROJECTIONS This Presentation contains financial forecasts for the Company with respect to certain financial results for the Company’s fiscal years 2020 through 2025. Neither TPAC’s nor Company’s independent auditors have audited, studied, reviewed, compiled or performed any proced
Slide 4: The Presenters
The Presenters P E A R T H E R A P E U T I C S T H I M B L E P O I N T A C Q U I S I T I O N COREY YURI CHRIS ELON JULIA MCCANN MARICICH BOMS GUIFFRE STRANDBERG MD, PHD MD, MBA MBA JD, MBA MBA CEO CFO & COO CMO CCO CEO 4The Presenters P E A R T H E R A P E U T I C S T H I M B L E P O I N T A C Q U I
Slide 5: Pear Therapeutics Transaction Overview
Pear Therapeutics Transaction Overview Pear is preparing to go public through a SPAC merger with Thimble Point Acquisition Corp. and has raised an oversubscribed $125.8 million PIPE to further support long-term growth Pe a r T h e r a p e u t i c s • Pear is the leading developer of software to trea
Slide 6: Pro Forma Transaction Summary
Pro Forma Transaction Summary P F O W N E R S H I P Estimated Sources and Uses ($ in millions) SOURCES PRO FORMA VALUATION 17% SPAC Cash in Trust $276.0 Illustrative Price per Share $10.0 (1) Founder Shares 56.3 Pro Forma Shares Outstanding (mm) 165.81 3% (2) PIPE 125.8 Equity Value 1,658.1 (3) (4)
Slide 7: Pear Therapeutics Investment Highlights
Pear Therapeutics Investment Highlights Transformational opportunity to disrupt the >$3T global healthcare industry with software-based therapeutics that can address unmet 1 medical needs alone and in combination with pharmaceuticals Emerging sector of prescription digital therapeutics (PDTs) = soft
Slide 8: Contents
Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Current Status & Path Forward Appendix 8Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, P
Slide 9: Growing burden of chronic disease
G R O W I N G B U R D E N O F C H R O N I C D I S E A S E Major trends 90% of U.S. $3.8 trillion in annual health T R A N S I T I O N care expenditures is for people with T O T E L E M E D I C I N E 1 chronic and mental health conditions converge Number of people who have used telehealth doubled, fr
Slide 10: Software can treat disease and enhance outcomes across nearly every disease
Pear believes software can treat disease and enhance outcomes across nearly every disease PRODUCTS PRODUCT CANDIDATES P D Ts C O U L D H E L P AC H I E V E D I S E A S E A D D I C T I O N I N S O M N I A PA I N C A N C E R E X A M P L E H E A LT H O U TC O M E S I N D I F F E R E N T WAY S C U R R E
Slide 11: Prescription Digital Therapeutics (PDTs) are software to treat serious disease
Prescription Digital Therapeutics (PDTs) are software to treat serious disease HEALTH AND PRESCRIPTION DIGITAL PHARMACEUTICALS WELLNESS APPS THERAPEUTICS Utilizes digital technology to improve human health Tested in randomized controlled trials FDA authorized safe and effective Provides real-time fe
Slide 12: PDTs are poised to disrupt care delivery
CLINICIANS PDTs are poised to Improve reach allowing for broader patient impact disrupt care delivery Reimbursable events for to benefit major stakeholders in dashboard interactions the healthcare system PATIENTS 24/7 remote access without fear of stigma Favorable side effect profile vs medications
Slide 13: Contents
Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Current Status & Path Forward Appendix 13Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product,
Slide 14: Pear is a pioneer in PDTs
P E A R P RO D U C T S I N M A J O R D E E P & I S A P I O N E E R M A R K E T S B ROA D P I P E L I N E Pear 1 2 3 Pear is the first FDA-authorized products 14 product Therapeutics mover and leader in reSET, reSET-O, and candidates with the the space, defining Somryst for the potential to improve t
Slide 15: Pear's business is tech enabled by life science
Pear’s business is T E C H L I F E S C I E N C E enabled by life science P L AT F O R M IP and tech Payor and provider Foundational estate integration including 20+ owned and competitive licensed patents advantages… R E G U L AT O RY D ATA Pathway requires clinical Products improve over evidence tim
Slide 16: Pear has similarities to disruptive life science and tech companies
…and we believe Pear has P L AT F O R M - D R I V E N P I O N E E R S T E C H P L AY E R S O F W I T H similarities to N E W T H E R A P E U T I C D O M I NA N T M O DA L I T I E S P L AT F O R M S disruptive life science and tech companies 16…and we believe Pear has P L AT F O R M - D R I V E N P I
Slide 17: Management and investors
M A N A G E M E N T I N V E S T O R S Pear’s team, $250m+ of capital raised to date COREY MCCANN, MD, PHD culture & investors President & CEO represent a CHRIS GUIFFRE, JD, MBA CFO & COO unique mix of life ERIN BRENNER * science and tech Chief Product Development Officer KATHY JEFFERY Chief People O
Slide 18: Contents
Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Current Status & Path Forward Appendix 18Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product,
Slide 19: Pear has 3 FDA-authorized products, 14 candidates, 100+ opportunities
Pear has… 3 14 100+ F D A P R O D U C T P R O D U C T A U T H O R I Z E D C A N D I D AT E S O P P O RT U N I T I E S P R O D U C T S I N P I P E L I N E L E V E R A G I N G P L A T F O R M 19Pear has… 3 14 100+ F D A P R O D U C T P R O D U C T A U T H O R I Z E D C A N D I D AT E S O P P O RT U N
Slide 20: Pear's first three commercial products
Pear’s first three commercial products designed to redefine care for major T O TA L A D D R E S S A B L E medical conditions M A R K E T 1 ( U S ) Only product FDA authorized to treat addiction to alcohol, cannabis, cocaine and stimulants $5B+ Only FDA-authorized software product that’s proven to he
Slide 21: Pear has a robust pipeline of product candidates
C O N T E N T P A R T N E R P R O D U C T T H E R A P E U T I C A R E A / I N D I C A T I O N D E V E L O P M E N T S T A G E Discovery POC Pivotal Commercial * Substance Use Disorder * Opioid Use Disorder Pear has Chronic Insomnia a robust pipeline Alcohol Use Disorder Schizophrenia Anxiety (GAD) o
Slide 22: Our PDT engine enables discovery, development and commercialization
Our PDT engine enables the discovery, development, and P L A T F O R M T O D I S C O V E R A N D P L A T F O R M C A P A B L E O F H O S T I N G 1 0 0 s O F r d D E V E L O P N E W P D T s P D T s B Y P E A R A N D 3 P A R T I E S commercialization of Component library of therapeutic Clinician dashb
Slide 23: Contents
Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Current Status & Path Forward Appendix 23Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product,
Slide 24: reSET and reSET-O redefine treatment of SUD and OUD
are designed to redefine treatment of and Substance Use Disorder (SUD) and Opioid Use Disorder (OUD) PAT I E N T C L I N I C I A N + • Cognitive Behavioral Therapy (CBT)• Real-World Engagement • Fluency Training• Concept proficiency • Contingency Management• Cravings & Triggers • Urine Drug Screens
Slide 25: Strong clinical and real-world outcomes
and show strong clinical and C L I N I C A L T R I A L S R E A L W O R L D U S E stronger improved abstinence of patients abstinent at 12 real-world 1 5 >2X for reSET 88% weeks outcomes of patients retained in of patients retained in therapy at 2 5 82% 85% therapy for reSET-O 12 weeks Up to substitu
Slide 26: Demonstrated commercial traction
have and demonstrated commercial traction 20,000+ 700+ 15 clinicians prescriptions organizations who have provided access* of providers were very satisfied or somewhat cost saving per Completed half of 3 1 satisfied with their overall patient all core modules 66% 82% $2,150 2 performance *Providing
Slide 27: Somryst: first-line drug-free treatment for chronic insomnia
: first-line drug-free treatment for 30 million Americans with chronic insomnia FDA-authorized to treat patients with chronic insomnia Examined in 29 completed or ongoing studies Delivers drug-free treatment without the risk of dependence and inappropriate long-term use Addresses supply-demand misma
Slide 28: Data show significant improvement in insomnia and depression endpoints
C L I N I C A L Decrease in the severity of 1 45% insomnia symptoms Data show significant Decrease in depression 2 >50% symptoms improvement Decrease in anxiety 2 ~45% symptoms in insomnia and Durable effect on insomnia, Up to 18 depression endpoints 3-4 depression, and anxiety MONTHS R E A L W O R
Slide 29: Contents
Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Current Status & Path Forward Appendix 29Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product,
Slide 30: Pear is poised for near-term commercial scale
Pear is poised for near-term commercial scale PROJECTED YE 2023 product candidates in POTENTIAL DRIVERS OF COMMERCIAL SCALE 3 pivotal studies S C R I P T V O L U M E product candidates 20 • Inclusion in clinical guidelines month HEOR data for reSET, • Deeper integration into health system infrastruc
Slide 31: Commercial and HEOR data flywheel
Scripts create additional patients treated, RWE, Our commercial and HEOR data points flywheel drives a RWE + virtuous cycle 02 PRESCRIPTIONS 01 HEOR DATA of commercial adoption… Coverage decisions Performance drive additional data drives prescription growth product enhancements COVERAGE 04 DECISIONS
Slide 32: Engine poised for pipeline growth and product commercialization
…and our engine is poised for pipeline growth and product commercialization D I S C O V E R Y D E V E L O P M E N T A C Q U I S I T I O N D E V E L O P M E N T C O M M E RC I A L E N G I N E P L AT F O R M P L AT F O R M ASSETS EVALUATED* Component library of therapeutics Multi-product clinician das
Slide 33: Multiple near-term milestones
Multiple 6-month HEOR data 9, 12-month HEOR data near-term 6-month HEOR value Adoption by large healthcare providers C O M M E RC I A L creation Coverage decisions by public and private payors milestones Ex-US expansion* Additional PDT candidates and digital biomarker licenses/acquisitions P I P E L
Slide 34: This financing boosts our position as category leader
This financing PDT Opportunities for Most Medical Conditions boosts our • Developed by Pear CARDIOVASCULAR DIABETES BEHAVIORAL HEALTH NEUROLOGY rd position and 3 parties • Mono therapies and drug/software combos as the long- RESPIRATORY ONCOLOGY OBESITY MUSCULOSKELETAL term category leader for Dynam
Slide 35: Pear is the category creator for PDTs
Pear is the category creator for PDTs Pear is the category creator Pear’s pipeline and platform are poised PDTs as treatment for most medical conditions to drive the space creating a represent a and market leader with a $2B+ $15B+ $250B+ serviceable available market from serviceable available market
Slide 36: Contents
Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product, Pipeline & Platform Overview Commercial Product Detail Current Status & Path Forward Appendix 36Contents The Opportunity For Prescription Digital Therapeutics Introducing Pear Therapeutics Product,
Slide 37: Category creators offer significant financial upside
Category creators offer significant financial upside Novel Electric Field-based Leading Chronic Disease Leading Liquid Reimagined Connected Oncology Treatment Management Software Biopsy Diagnostics Dialysis Machines Technology ** $26 BN+ Market Cap $18 BN+ Market Cap $12 BN+ Market Cap $2 BN+ Market
Slide 38: Compelling moment to join Pear
This is a compelling moment to join Pear and the future of PDTs U N I Q U E O P P O RT U N I T Y T O I N V E S T E A R LY R E V E N U E F O R E C A S T I N VA LUAT I O N T R A J E C TO RY $ in millions $125 Pear’s Implied $ in millions $3,147 Value at YE ’22 Discounted to $2,394 Today $22 vs Current
Slide 39: Attractive entry value relative to disruptive healthcare peers
Attractive entry value relative to disruptive healthcare peers Category leaders pioneering approaches to address unmet needs using novel and unique ideology First-mover advantage contributing to acceleration of revenue and profitability momentum 33.07x EV/ 2023E Revenue 37% 17.57x 16.88x 16.69x Medi
Slide 40: Pear is priced at a discount to life science comparables
Pear is priced at a discount to life science comparables Therapeutics targeting psychiatric and neurological diseases $6,000 $9,000 $10,000 $5,000 5,000 $5,000 $4,000 $4,000 3,113 $3,000 $3,000 2,777 2,051 $2,000 $2,000 ** 1,701 1,638 * $1,201 1,153 $1,000 $1,000 $0 $0 Phase 2 Phase 3 Commercial Pha
Slide 41: Value creation analogous to biopharma platforms
Value Creation analogous to biopharma platforms Pear’s PDT leadership is no less innovative than other biopharma platform companies that brought unorthodox technologies to caregivers, patients and health systems Pioneering developer of Pole position in the development of A sharp departure from prior
Slide 42: First PDTs FDA-authorized to treat addiction
and First-ever PDT to achieve FDA medical claims to treat disease are the first PDTs FDA-authorized to treat addiction for 21.2M Americans suffering from addiction to alcohol, cannabis, cocaine, 1 and stimulants Two successful RCTs in >1,000 SUD patients 2-3 (alcohol, cannabis, cocaine, stimulants)
Slide 43: reSET pivotal trial outcomes
A B S T I N E N C E R AT E S B Y T R E AT M E N T G RO U P What are the top-line outcomes from the rTAU* + reSET (n=206) 40.3% reSET Pivotal Trial? TAU (n=193) 17.6% P=.0004 * 1 HIGHLIGHTS CLINICAL OUTCOMES SUMMARY FROM 12-WEEK PIVOTAL TRIAL P E RC E N TA G E OF PAT I E N T S W H O C O M P L E T E D
Slide 44: reSET-O pivotal trial outcomes
A B S T I N E N C E R AT E S B Y T R E AT M E N T G RO U P What are the top-line outcomes from the TAU* + reSET-O (n=91) 77.3% reSET-O Pivotal Trial? TAU (n=79) 62.1% P=.02 * T R E AT M E N T P RO G R A M 1,2 HIGHLIGHTS CLINICAL OUTCOMES SUMMARY FROM 12-WEEK PIVOTAL TRIAL R E T E N T I O N R AT E Pa
Slide 45: Economic impact of reSET-O in the real world
What is the Economic Impact of the product in the real world? In a published analysis of Real-World Evidence, patients using reSET-O® used fewer costly healthcare resources after 1 they began treatment • Study of 351 patients who used 1 + + reSET-O Inpatient Emergency Post-Surgical • 82% of patients
Slide 46: Outcomes of the Somryst pivotal trial
What were the outcomes of the Somryst pivotal trial? ® IN TWO RANDOMIZED CONTROLLED TRIALS THAT EVALUATED >1400 ADULTS WITH CHRONIC INSOMNIA, SOMRYST USE 1-3 RESULTED IN A SIGNIFICANT REDUCTION IN INSOMNIA SEVERITY SYMPTOMS, AND THE REDUCTION WAS MAINTAINED OVER 12 MONTHS. 1 2 STUDY 1 STUDY 2 Mean I
Slide 47: Patient engagement in the real world
What does patient engagement look like in the real world? R E A L W O R L D S T U DY D E S I G N H E A LT H O U T C O M E S Patient Engagement ISI Score 100% • 7,414 patients utilized Somryst in a pre- 19 88% 100 18 20 77% 1-3 15 commercial pilot study 80 67% 60% 13 15 53% 11 60 10 10 40 • Patients
Slide 48: Risk Factors
Risk Factors The below list of risk factors has been prepared as part of the Business Combination. The risks presented below are certain of the general risks related to the business of the Company, TPAC and the Business Combination and such list is not exhaustive. The list below is qualified in its
Slide 49: Risk Factors: Financial Position
Risk Factors Risks Related to the Company’s Financial Position · The Company has a history of significant losses, anticipates increasing expenses in the future, and may not be able to achieve or maintain profitability. · Due to the resources required for the development of the Company’s pipeline, an
Slide 50: Risk Factors: Regulatory Compliance and Legal Matters
Risk Factors Risks Related to the Company’s Regulatory Compliance and Legal Matters · We operate in a highly regulated industry and are subject to a wide range of federal, state and local laws, rules and regulations, including FDA regulatory requirements and laws pertaining to fraud and abuse in hea
Slide 51: Risk Factors: Financial Reporting
Risk Factors Risks Related to the Company’s Financial Reporting · We rely on assumptions, estimates, and business data to calculate our key performance indicators and other business metrics, and real or perceived inaccuracies in these metrics may harm our reputation and negatively affect our busines
Slide 52: References
References Slide 6 1. https://www.cnbc.com/2017/01/17/tech-set-to-transform-3-trillion-health-care-industry.html Slide 8 1. https://www.cdc.gov/chronicdisease/about/costs/index.htm 2. https://azbigmedia.com/business/future-of-telehealth-is-brighter-than-ever-in-the-wake-of-covid-19/ 3. https://www.a
Slide 53: References
References Slide 25 1. Yuri A. Maricich, MD, Xiaorui Xiong, PhD, Robert Gerwien, PhD, Alice Kuo, BA Fulton Velez, MD MBA, Bruce Imbert, MD PhD, Keely Boyer, MBA, Hilary F. Luderer, PhD, Stephen Braun, BA, Karren Williams, PhD (2020): Real-World evidence for a prescription digital therapeutic to trea
Slide 54: References
References Slide 43 1. Campbell et al., American Journal of Psychiatry. 2014. 171(6):683-690. 2. Yuri A. Maricich, Warren K. Bickel, Lisa A. Marsch, Kirstin Gatchalian, Jeffrey Botbyl & Hilary F. Luderer (2020): Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine